

# National Influenza Vaccine Summit Newsletter



Issue 2 / July 2006

*The American Medical Association (AMA) and the Centers for Disease Control and Prevention (CDC) co-sponsor the National Influenza Vaccine Summit (The Summit). The Summit is an action-oriented entity with over 400 members who represent over 100 public and private organizations with an interest in addressing and resolving influenza and influenza vaccine issues.*

## Second National Influenza Vaccine Summit , June 2006

A second National Influenza Vaccine Summit was convened this year in Chicago, Illinois on June 22. One hundred forty-seven individuals representing seventy-three stakeholder organizations attended and participated in the summit. The goal of this summit meeting was to discuss strategies that may increase utilization of influenza vaccine during the upcoming vaccination season. In addition to considerable discussion among summit members, ten presentations were made by key stakeholders. Presentation slides are available at [www.ama-assn.org/go/influenzasummit](http://www.ama-assn.org/go/influenzasummit).

During the final session of the summit, participants organized six teams that will work to target three populations and address three important objectives for the upcoming influenza season. Each team will develop plans that seek to increase the level of vaccine uptake during the upcoming influenza season. Team leaders are actively recruiting members so that these plans may be developed and implemented by August 31. The six teams are as follows:

1. Targeting healthcare workers;
2. Targeting children aged 6 months through 18 years;
3. Targeting all contacts of high-priority population with an eye towards "universal vaccination;
4. Extending the vaccination season;
5. Unifying/creating a provider toolkit; and
6. Utilizing Partnerships to improve education, reduce barriers to immunizing, and share the fiscal risk of influenza vaccine.

If you are interested in participating in one of these teams, would like additional information regarding this and previous Summits, or are interested in other information regarding influenza vaccination during the upcoming influenza season, go to [www.ama-assn.org/go/influenzasummit](http://www.ama-assn.org/go/influenzasummit).

National Influenza Vaccine Summit Newsletter  
Issue 2, July 2006

## Influenza Vaccine Supply and Production

The National Influenza Vaccine Summit has made a commitment to provide information on important issues concerning the upcoming influenza season. As part of that effort, we want to let you know about a recent FDA action that concerns influenza vaccine for the 2006-07 season. The links found on the following web sites will provide you with information related to this issue.

- [National Influenza Vaccine Summit statement, July 18, 2006](#)
- [FDA letter to sanofi pasteur, June 30, 2006](#)
- [FDA Questions and Answers regarding FDA letter, July 3, 2006](#)
- [Sanofi pasteur statement, July 3, 2006](#)

The National Influenza Vaccine Summit will continue to monitor the situation and keep you informed of developments.

### Projection of the 2006-07 Influenza Vaccine Supply

As of June 9, 2006, influenza vaccine manufacturers project that approximately 100 million doses of influenza vaccine will be available in the U.S. for use during the 2006-07 influenza season. This amount represents approximately 16% more doses than were available for the 2005-06 season. An additional 15 million doses may become available if another manufacturer's vaccine is licensed in 2006.

Also as of June 9, 2006, sanofi pasteur projects that up to 8 million doses of thimerosal-free vaccine in pre-filled syringes or vials will be produced for the 2006-07 influenza season. The majority of this vaccine will be in 0.25 mL syringes (indicated for ages 6-35 months) with the remainder in 0.5 mL vials or syringes (indicated for ages 36 months and older). In addition, GSK's influenza vaccine for adults 18 years of age and older is preservative-free (trace thimerosal) vaccine and Novartis (formerly Chiron) has a preservative-free (trace thimerosal) preparation for persons 4 years of age and older. The nasal influenza vaccine, FluMist, also is thimerosal-free.

GlaxoSmithKline (GSK) submitted a Biologics License Application (BLA) to the FDA for FluLaval, a seasonal, inactivated influenza vaccine, and hopes to receive approval for use in persons aged 18 years and older in time for the 2006-07 influenza season. If approved, GSK projects up to 15 million doses of FluLaval will be available in the US for the 2006-07 influenza season.

## Influenza Vaccine Distribution and Administration

### Ordering Influenza Vaccine

Much of the influenza vaccine was pre-booked early this year. Providers should contact distributors and local vendors about remaining supply. Additional doses may be available if a new vaccine is licensed in 2006.

### Influenza vaccine preparations and their indications as licensed by the FDA

The table below has been updated with new information provided by GlaxoSmithKline, Inc. since the June 2006 publication of the National Influenza Vaccine Summit newsletter. GlaxoSmithKline, Inc. informed the Summit that the level of Thimerosal in Fluarix<sup>TM</sup> inactivated TIV is <1µg Hg/0.5mL dose, preservative free.

**TABLE. Influenza Vaccine Manufacturers for the 2006-07 Influenza Season**

Manufacturer	Vaccine	Formulation	Thimerosal preservative	Age indication
sanofi pasteur, Inc.	Fluzone®, Inactivated TIV	Multi-dose vial	Yes	≥ 6 months
		Single-dose pre-filled 0.5 mL syringe or vial	None	≥ 36 months
		Single-dose pre-filled 0.25 mL syringe	None	6-35 months
MedImmune Vaccines, Inc	FluMist <sup>TM</sup> LAIV	Single-dose sprayer	None	Healthy persons 5-49 years
Novartis Vaccine (formerly Chiron Corporation)	Fluvirin <sup>TM</sup> Inactivated TIV	Multi-dose vial	Yes	≥ 4 years
		Single-dose 0.5 mL syringe	<1µg Hg/0.5mL dose, preservative free	≥ 4 years
GlaxoSmithKline, Inc.	Fluarix <sup>TM</sup> Inactivated TIV	Single-dose pre-filled syringe 0.5 mL	<1µg Hg/0.5mL dose, preservative free	≥ 18 years

### **Advisory Committee on Immunization Practices (ACIP)**

The ACIP met June 29–30, 2006 in Atlanta, Georgia. The agenda included discussion and votes on recommendations for Influenza vaccine, Quadrivalent Human Papillomavirus vaccine (HPV), Tdap vaccine and Varicella vaccine. Other topics for discussion included use of Pneumococcal vaccines to reduce morbidity and mortality in an influenza pandemic, Menactra<sup>®</sup> supply and prioritization, Herpes Zoster (Shingles) vaccine, the Adult Immunization Schedule, and the Childhood Immunization Schedule for 2007. Slide presentations from the meeting are currently available at <http://www.cdc.gov/nip/ACIP/slides/mtg-slides-jun06.htm>. Meeting minutes will be available at [www.cdc.gov/nip/ACIP/minutes.htm](http://www.cdc.gov/nip/ACIP/minutes.htm) later this year.

### **Morbidity and Mortality Weekly Reports (MMWRs)**

To review recently published MMWRs related to influenza, visit the following MMWR links.

- “Prevention and Control of Influenza, Recommendations of the Advisory Committee on Immunization Practices (ACIP),” MMWR July 28, 2006; 55(RR10);1–42  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm>
- “Update: Influenza Activity—United States and Worldwide, 2005–06 Season, and Composition of the 2006–07 Influenza Vaccine,” MMWR June 16, 2006; 55(23);648–653 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5523a2.htm>
- “Influenza Vaccination of Health-Care Personnel, Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP),” MMWR February 24, 2006; 55(RR02);1–16 <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm>
- “High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents—United States, 2005–06 Influenza Season,” MMWR January 20, 2006, 55(02);44–46  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5502a7.htm>

### **Influenza ListServe**

Individual subscriptions to the influenza listserv should be emailed to [listserv@listerv.cdc.gov](mailto:listserv@listerv.cdc.gov). Type subscribe flu-serv in the body of the email. Previous influenza vaccine bulletins are available on the CDC website at <http://www.cdc.gov/flu/professionals/flubulletin.htm>.

### **Upcoming Events**

Seventh National Conference on Immunization Coalitions, August 9–11, 2006, Denver, Colorado, <http://www.seeuthere.com/rsvp/invitation/invitation.asp?id=/m2c666-455170415278>

National Adult Immunization Awareness Week, September 24–30, 2006, Nationwide, <http://www.cdc.gov/nip/events/naiaw/>